
<html>
<head>
<style type="text/css" media="print">
.hide {
	display: none
}
</style>
</head>
<body style="margin: 0; padding: 0">

<div class="hide">


<div align="center">
<table width="0" border="2" cellspacing="0">

	<tr valign="top">
		<td width="100%" bgcolor="#E6E6E6" colspan="3"><font size="1"
			face="Arial"><b>Evidence-based drugs and oral doses for
		Systolic Heart Failure </b><sup><b>1</b></sup></font></td>
	</tr>
	<tr valign="top">
		<td width="33%"><font size="1" face="Arial"><b>Drug</b></font></td>
		<td width="33%"><font size="1" face="Arial"><b>Start
		Dose</b></font></td>
		<td width="32%"><font size="1" face="Arial"><b>Effective
		Target Dose Range</b><sup><b>2</b></sup></font></td>
	</tr>
	<tr valign="top">
		<td width="100%" bgcolor="#F3F3F3" colspan="3"><font size="1"
			face="Arial"><b>ACEI</b></font></td>
	</tr>

	<tr valign="top">
		<td width="33%"><font size="1" face="Arial">Captopril</font></td>
		<td width="33%"><font size="1" face="Arial">6.25mg - 12.5
		mg tid</font></td>
		<td width="32%"><font size="1" face="Arial">25mg - 50mg
		tid</font></td>
	</tr>
	<tr valign="top">
		<td width="33%"><font size="1" face="Arial">Enalapril</font></td>
		<td width="33%"><font size="1" face="Arial">1.25mg - 2.5mg
		bid</font></td>
		<td width="32%"><font size="1" face="Arial">10mg bid</font></td>
	</tr>
	<tr valign="top">
		<td width="33%"><font size="1" face="Arial">Ramipril</font></td>

		<td width="33%"><font size="1" face="Arial">1.25mg - 2.5mg
		bid</font></td>
		<td width="32%"><font size="1" face="Arial">5mg bid</font></td>
	</tr>
	<tr valign="top">
		<td width="33%"><font size="1" face="Arial">Lisinopril</font></td>
		<td width="33%"><font size="1" face="Arial">2.5mg - 5mg od</font></td>
		<td width="32%"><font size="1" face="Arial">20mg - 35mg od</font></td>
	</tr>
	<tr valign="top">
		<td width="100%" bgcolor="#F3F3F3" colspan="3"><font size="1"
			face="Arial"><b>&beta; -Blocker</b></font></td>
	</tr>
	<tr valign="top">
		<td width="33%"><font size="1" face="Arial">Metoprolol
		tartrate</font></td>

		<td width="33%"><font size="1" face="Arial">12.5mg/day
		(given bid)</font></td>
		<td width="32%"><font size="1" face="Arial">100 - 200
		mg/day (given bid)</font></td>
	</tr>
	<tr valign="top">
		<td width="33%"><font size="1" face="Arial">Bisoprolol </font></td>
		<td width="33%"><font size="1" face="Arial">1.25mg od</font></td>
		<td width="32%"><font size="1" face="Arial">10mg od</font></td>
	</tr>
	<tr valign="top">
		<td width="33%"><font size="1" face="Arial">Carvedilol * </font></td>

		<td width="33%"><font size="1" face="Arial">3.125mg bid</font></td>
		<td width="32%"><font size="1" face="Arial">25mg bid</font></td>
	</tr>
	<tr valign="top">
		<td width="100%" bgcolor="#F3F3F3" colspan="3"><font size="1"
			face="Arial"><b>ARB</b></font></td>
	</tr>
	<tr valign="top">
		<td width="33%"><font size="1" face="Arial">Candesartan **</font></td>
		<td width="33%"><font size="1" face="Arial">4mg od</font></td>
		<td width="32%"><font size="1" face="Arial">32mg od</font></td>
	</tr>
	<tr valign="top">
		<td width="33%"><font size="1" face="Arial">Valsartan</font></td>

		<td width="33%"><font size="1" face="Arial">40mg bid</font></td>
		<td width="32%"><font size="1" face="Arial">160mg bid</font></td>
	</tr>
	<tr valign="top">
		<td width="100%" bgcolor="#F3F3F3" colspan="3"><font size="1"
			face="Arial"><b>Aldosterone antagonist</b></font></td>
	</tr>
	<tr valign="top">
		<td width="33%"><font size="1" face="Arial">Spironolactone
		***</font></td>
		<td width="33%"><font size="1" face="Arial">12.5mg od</font></td>
		<td width="32%"><font size="1" face="Arial">50mg od</font></td>
	</tr>
	<tr valign="top">
		<td width="100%" colspan="3"><font size="1" face="Arial">*
		Contained within the American College of Cardiology/American Heart
		Association Practice Guidelines</font> <br>
		<font size="1" face="Arial">** Not recommended for heart
		failure with PSF</font> <br>
		<font size="1" face="Arial">***Spironolactone can increase
		serum potassium, especially during an acute dehydrating illness where
		renal dysfunction can worsen. </font></td>
	</tr>
</table>
</div>
<br>
<div align="left">
<table>
	<tr valign="top">
		<td colspan=2 width="100%"><font size="1" face="Arial"><b><u>Polypharmacy
		Combinations and Potential Drug Interactions:</u></b></font></td>
	</tr>
	<tr>
		<td><font size="1" face="Arial">Amiodarone &phi; / &beta;
		-Blocker</font></td>
		<td><font size="1" face="Arial">Can increase the effect of
		the &beta; -Blocker </font></td>
	</tr>
	<tr>
		<td><font size="1" face="Arial">Amiodarone &phi; /
		Warfarin</font></td>
		<td><font size="1" face="Arial">Can increase the effect of
		Warfarin</font></td>
	</tr>
	<tr>
		<td><font size="1" face="Arial">Amiodarone &phi; / Digoxin</font>
		</td>
		<td><font size="1" face="Arial">Can increase serum Digoxin
		levels ~ 2 fold</font> <br>
		</td>
	</tr>
	<tr>
		<td><font size="1" face="Arial">Digoxin / &beta; -Blocker</font>
		</td>
		<td><font size="1" face="Arial">Carvedilol may increase
		Digoxin levels ~25%; added pharmacological effect on heart rate</font></td>
	</tr>
	<tr>
		<td><font size="1" face="Arial">Digoxin / Loop Diuretics</font></td>
		<td><font size="1" face="Arial">Can increase the Digoxin
		effect</font></td>
	</tr>
	<tr>
		<td><font size="1" face="Arial">Digoxin / Spironolactone</font></td>
		<td><font size="1" face="Arial">May increase Digoxin
		levels</font></td>
	</tr>
	<tr>
		<td><font size="1" face="Arial">Spironolactone /ACEI or
		ARB</font></td>
		<td><font size="1" face="Arial">Can elevate serum
		potassium levels</font></td>
	</tr>
	<tr>
		<td><font size="1" face="Arial">ACEI / ARB </font></td>
		<td><font size="1" face="Arial">This combination is
		indicated in patients with impaired LVSF when they remain symptomatic
		(i.e. NYHA II-IV) despite OPTIMAL dosage of ACEI and &beta; -blockers.
		Close monitoring of renal function is required due to increased risk.
		</font></td>
	</tr>
	<tr>
		<td><font size="1" face="Arial">Calcium channel blockers
		and/or NSAIDs</font></td>
		<td><font size="1" face="Arial">Can exacerbate heart
		failure and should be avoided</font></td>
	</tr>
	<tr>
		<td colspan=2><font size="1" face="Arial">&phi; Close
		monitoring of TSH and LFT is recommended to avoid Amiodarone toxicity</font>
		</td>
	</tr>

</table>
</div>
<br>
<a name="0.3_table04"></a>
<div align="left">
<table width="0">
	<tr valign="top">
		<td width="100%" height="15"><font size="1" face="Arial"><b><u>Indications
		of Pharmacologic Intolerance:</u></b></font>
		<ul type="DISC">
			<li><font size="1" face="Arial">Symptomatic hypotension:
			Check blood pressure supine and erect to determine if present, may
			require slower uptitration</font></li>
			<li><font size="1" face="Arial">Renal dysfunction: An
			increase in serum potassium and creatinine beyond an acceptable
			elevation threshold</font></li>
			<li><font size="1" face="Arial">Bradycardia</font></li>

		</ul>
		</td>
	</tr>
</table>
</div>
<br>
<a name="0.3_table05"></a>
<div align="left">
<table width="0">
	<tr valign="top">
		<td width="100%" colspan="2"><font size="1" face="Arial"><b><u>Treatment
		of Heart Failure with PSF</u></b></font>
		<p><font size="1" face="Arial">Recommendations for
		treatment of this condition remain speculative because of the limited
		data available on various therapies however, the Canadian
		Cardiovascular Society endorses the following: </font> <br>
		</p>
		<p><font size="1" face="Arial"><b>Practical Tips:</b></font></p>

		<ul type="DISC">
			<li><font size="1" face="Arial">It is very important to
			control the co-morbidities, such as hypertension and diabetes
			mellitus, that are often associated with heart failure with PSF</font></li>
			<li><font size="1" face="Arial">Diuretics should not be
			used excessively due to risk of decreasing cardiac output and
			compromise of renal function</font></li>
		</ul>
		</td>
	</tr>
	<tr valign="top">
		<td width="20%"><font size="1" face="Arial">ACEI</font></td>
		<td width="79%"><font size="1" face="Arial">May improve
		relaxation and cardiac distensibility directly and should be
		considered for most patients </font></td>
	</tr>
	<tr valign="top">
		<td width="20%"><font size="1" face="Arial">&beta;
		-Blocker</font></td>
		<td width="79%"><font size="1" face="Arial">May be useful
		to improve symptoms by decreasing heart rate and increasing diastolic
		filling time and should be considered for most patients </font></td>
	</tr>
	<tr valign="top">
		<td width="20%"><font size="1" face="Arial">ARBs</font></td>
		<td width="79%"><font size="1" face="Arial">May be
		considered to reduce heart failure hospitalizations </font></td>
	</tr>
	<tr valign="top">
		<td width="20%"><font size="1" face="Arial">Diuretics</font></td>
		<td width="79%"><font size="1" face="Arial">Should be used
		to control pulmonary congestion and peripheral edema </font></td>
	</tr>

	<tr valign="top">
		<td width="20%"><font size="1" face="Arial">Calcium
		channel blockers </font></td>
		<td width="79%"><font size="1" face="Arial">May be
		considered to minimize symptoms of heart failure</font></td>
	</tr>
	<tr valign="top">
		<td width="20%"><font size="1" face="Arial">Digoxin</font></td>
		<td width="79%"><font size="1" face="Arial">May be
		considered to minimize symptoms of heart failure </font></td>
	</tr>
</table>
</div>
<br>
<a name="0.3_table06"></a>
<div align="left">
<table width="0">
	<tr valign="top">
		<td width="100%"><font size="1" face="Arial"><b><u>Recommendations
		on the use of </u>&beta; <u>-Blockers</u></b></font></td>
	</tr>
	<tr valign="top">
		<td>
		<ul type="DISC">
			<li><font size="1" face="Arial">All heart failure
			patients with an LVEF equal to or less than 40% should receive a
			b-blocker proven to be beneficial in large-scale clinical trials </font></li>
			<li><font size="1" face="Arial">Patients with NYHA class
			I or II can be safely initiated and titrated with a &beta; -blocker
			by non-specialist physicians</font></li>
			<li><font size="1" face="Arial">Patients with NYHA class
			III - IV symptoms, close monitoring is required by a physician
			experienced in the care of heart failure patients</font></li>
			<li><font size="1" face="Arial">Patients with NYHA class
			IV symptoms should be stabilized before initiation of a &beta;
			-blocker</font></li>
			<li><font size="1" face="Arial">Therapy should be
			initiated at a low dose and <u>slowly</u> titrated to the target dose
			used in large-scale clinical trials or the maximum tolerated dose if
			less than the target dose </font></li>
			<li><font size="1" face="Arial">If concomitant reactive
			airways disease is present, consider using more selective &beta; 1
			blockade (eg. Bisoprolol, Metoprolol)</font></li>
			<li><font size="1" face="Arial">If the patient is
			hypotensive, consider reducing the dose of other medications or
			change the timing of medications before reducing the b-blocker
			dosage.</font></li>
			<li><font size="1" face="Arial">If AV block is present,
			consider decreasing other AV blocking drugs, such as digoxin or
			amiodarone.</font></li>
		</ul>
		</td>
	</tr>
	<tr valign="top">
		<td><br>
		<font size="1" face="Arial"><b><u>&beta; -Blockers are
		contraindicated in patients with the following conditions:</u></b></font></td>
	</tr>
	<tr valign="top">
		<td>
		<ul type="DISC">
			<li><font size="1" face="Arial">Symptomatic hypotension
			despite adjustment of other therapies</font></li>
			<li><font size="1" face="Arial">Severe reactive airways
			disease (stable chronic obstructive pulmonary disease is not a
			contraindication) </font></li>
			<li><font size="1" face="Arial">Symptomatic bradycardia</font></li>
			<li><font size="1" face="Arial">Significant
			atrioventricular block without a permanent pacemaker </font></li>
		</ul>
		</td>
	</tr>
</table>

</div>
</body>
</html>
